These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Vigne S; Germi R; Duraffour S; Larrat S; Andrei G; Snoeck R; Garin D; Crance JM Antivir Ther; 2008; 13(3):357-68. PubMed ID: 18572748 [TBL] [Abstract][Full Text] [Related]
43. Therapeutic oligonucleotides: the state-of-the-art in purification technologies. Sanghvi YS; Schulte M Curr Opin Drug Discov Devel; 2004 Nov; 7(6):765-76. PubMed ID: 15595437 [TBL] [Abstract][Full Text] [Related]
44. Chemotherapy for recurrent and metastatic cervical cancer. Tao X; Hu W; Ramirez PT; Kavanagh JJ Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239 [TBL] [Abstract][Full Text] [Related]
45. Overview of target validation and the impact of oligonucleotides. Jones SW; Lindsay MA Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056 [TBL] [Abstract][Full Text] [Related]
46. Human papillomavirus testing for primary cervical cancer screening. Grce M; Davies P Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808 [TBL] [Abstract][Full Text] [Related]
47. [Future prospects of RNA interference in cancer therapies]. Ashihara E Rinsho Ketsueki; 2009 Oct; 50(10):1577-88. PubMed ID: 19915369 [No Abstract] [Full Text] [Related]
49. Antisense treatments for biothreat agents. Warfield KL; Panchal RG; Aman MJ; Bavari S Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760 [TBL] [Abstract][Full Text] [Related]
50. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Mullenders J; Bernards R Oncogene; 2009 Dec; 28(50):4409-20. PubMed ID: 19767776 [TBL] [Abstract][Full Text] [Related]
52. Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Ngamcherdtrakul W; Castro DJ; Gu S; Morry J; Reda M; Gray JW; Yantasee W Cancer Treat Rev; 2016 Apr; 45():19-29. PubMed ID: 26930249 [TBL] [Abstract][Full Text] [Related]
53. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. Jung HS; Rajasekaran N; Ju W; Shin YK J Clin Med; 2015 May; 4(5):1126-55. PubMed ID: 26239469 [TBL] [Abstract][Full Text] [Related]
57. Intranasal antisense therapy: preclinical models with a clinical future? Bitko V; Barik S Curr Opin Mol Ther; 2007 Apr; 9(2):119-25. PubMed ID: 17458164 [TBL] [Abstract][Full Text] [Related]
58. Oral delivery of small RNA and DNA. Forbes DC; Peppas NA J Control Release; 2012 Sep; 162(2):438-45. PubMed ID: 22771979 [TBL] [Abstract][Full Text] [Related]
59. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs. Jing X; Arya V; Reynolds KS; Rogers H Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914 [TBL] [Abstract][Full Text] [Related]
60. A status update of modified oligonucleotides for chemotherapeutics applications. Sanghvi YS Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]